Axsome Therapeutics, Inc.
corporate_fare Company Profile
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for AXSM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AXSM spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Axsome Q3: Revenue Up 52% to $259.7M, Net Loss Narrows to $12.9M
- Axsome Q3 Revenue Jumps 52% to $259.7M, Tops $1B Annualized Run Rate
- Axsome Posts 25-Cent Q3 Loss Per Share
- AUVELITY's Alzheimer's launch propels Axsome to $218M in Q2 revenue, a 46% surge; credit line expanded
- Axsome Q2 Revenue Jumps 46% to $218M, AUVELITY Alzheimer's Launch Drives Growth
Financial Snapshot
Short Interest & Short Volume
3.35 days to coverFINRA reported short interest of 3,263,105 shares in AXSM as of the October 30, 2026 settlement, a 4.9% increase from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 54.0% of AXSM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.